Close this search box.
Close this search box.
With sepsis, every hour counts
Target therapy sooner, with species identification before the second dose of empiric therapy

The first and only FDA-cleared diagnostic tests to provide species identification of sepsis-causing bacterial and fungal pathogens, directly from a whole blood sample and independent of a positive blood culture.

T2Candida Case Study
Secondary Candidemia in Critically Ill COVID-19 Patient

T2Candida enabled the detection of candidemia 29 hours before a positive blood culture was returned. Early detection allowed for the rapid initiation of antifungal therapy in a critically ill COVID-19 patient.

Enhancing the standard of care.

With T2 Biosystems, hospitals can identify sepsis-causing pathogens faster and more accurately than the standard of blood culture alone

Hospitals trust in T2 technology

Gregorio Marañón Hospital in Madrid, Spain
Two 2018 studies from Gregorio Marañón Hospital in Madrid, Spain.
Rigshospitalet, Denmark
"T2Candida was superior to blood culture and mannan antigen and may improve diagnosis."
Gemelli Hospital, Italy
66.7% of the clinically infected patients missed by blood culture were correctly identified by T2Bacteria
La Paz Hospital University, Spain
T2Candia Panel contributed to the healthy discharge of a 1-year-old transplant patient.

Patient Case Studies

Real stories about the positive impact of T2 Biosystems on clinical decisions and outcomes

Numbers don't lie.

Sepsis is a burden on healthcare and patients, contributing to:

Improve Outcomes more bold-01
∼50 million
cases per year
Worldwide Deaths
11 million
deaths annually, worldwide.
1 in 3
1 in 5
deaths worldwide
Integrate T2 Biosystems Panels into your hospital today!